A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
Squamous Cell Carcinoma of Head and Neck
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 287 (planned)
- Started
- Apr 22, 2024
- Main results expected
- Dec 27, 2032
- Fully finished
- Jul 28, 2033
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Cohorts 1, 2, 3B, 4 and 5: Objective Response Rate
Measured over: 2 years and 2 months
Cohort 3A: Number of Participants With Dose-limiting Toxicities (DLT)
Measured over: Up to 21 days
Cohort 3A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) as a Measure of Severity
Measured over: 2 years and 1 month
Cohort 6: Major Pathologic Response (MPR)
Measured over: 2 years and 2 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06385080 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC